Keros Therapeutics Stock Performance
| KROS Stock | USD 11.22 0.22 1.92% |
The company secures a Beta (Market Risk) of -0.0788, which conveys not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Keros Therapeutics are expected to decrease at a much lower rate. During the bear market, Keros Therapeutics is likely to outperform the market. At this point, Keros Therapeutics has a negative expected return of -0.62%. Please make sure to verify Keros Therapeutics' treynor ratio, accumulation distribution, as well as the relationship between the Accumulation Distribution and price action indicator , to decide if Keros Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Keros Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in April 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors. ...more
Actual Historical Performance (%)
One Day Return (1.92) | Five Day Return (3.94) | Year To Date Return (29.52) | Ten Year Return (44.12) | All Time Return (44.12) |
1 | Piper Sandler Lowers Keros Therapeutics Price Target to 15.00 | 01/17/2025 |
2 | Heres Why Were Not Too Worried About Keros Therapeutics Cash Burn Situation | 01/28/2025 |
3 | Keros Therapeutics to Present at the Guggenheim SMID Cap Biotech Conference | 01/30/2025 |
4 | FMR LLC Reduces Stake in Keros Therapeutics Inc. | 02/07/2025 |
5 | Acquisition by Rovaldi Christopher of 60000 shares of Keros Therapeutics subject to Rule 16b-3 | 02/18/2025 |
6 | Kairos Pharma Presents Preclinical Data on its Investigational Compounds KROS 101 and KROS 401 Further Supporting Both Compounds Potential as Therapeutics for M... | 02/26/2025 |
7 | Keros Therapeutics Full Year 2024 Earnings Misses Expectations | 02/28/2025 |
8 | Equities Analysts Set Expectations for KROS Q1 Earnings - MarketBeat | 03/06/2025 |
9 | Acquisition by Knowles Julius of 10000 shares of Keros Therapeutics at 46.31 subject to Rule 16b-3 | 03/07/2025 |
10 | How Has Keros Therapeutics Attracted Institutional Capital | 03/21/2025 |
| Begin Period Cash Flow | 332.4 M |
Keros |
Keros Therapeutics Relative Risk vs. Return Landscape
If you would invest 1,712 in Keros Therapeutics on December 23, 2024 and sell it today you would lose (590.00) from holding Keros Therapeutics or give up 34.46% of portfolio value over 90 days. Keros Therapeutics is currently does not generate positive expected returns and assumes 3.6484% risk (volatility on return distribution) over the 90 days horizon. In different words, 32% of stocks are less volatile than Keros, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Keros Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Keros Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Keros Therapeutics, and traders can use it to determine the average amount a Keros Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1703
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | KROS |
Estimated Market Risk
| 3.65 actual daily | 32 68% of assets are more volatile |
Expected Return
| -0.62 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.17 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Keros Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Keros Therapeutics by adding Keros Therapeutics to a well-diversified portfolio.
Keros Therapeutics Fundamentals Growth
Keros Stock prices reflect investors' perceptions of the future prospects and financial health of Keros Therapeutics, and Keros Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Keros Stock performance.
| Return On Equity | -0.41 | ||||
| Return On Asset | -0.27 | ||||
| Operating Margin | (17.51) % | ||||
| Current Valuation | (85.96 M) | ||||
| Shares Outstanding | 40.56 M | ||||
| Price To Book | 0.80 X | ||||
| Price To Sales | 128.20 X | ||||
| Revenue | 3.55 M | ||||
| Gross Profit | (14.74 M) | ||||
| EBITDA | (185.82 M) | ||||
| Net Income | (187.35 M) | ||||
| Cash And Equivalents | 215.62 M | ||||
| Cash Per Share | 8.37 X | ||||
| Total Debt | 18.86 M | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 14.39 X | ||||
| Book Value Per Share | 14.09 X | ||||
| Cash Flow From Operations | (160.87 M) | ||||
| Earnings Per Share | (5.00) X | ||||
| Market Capitalization | 455.11 M | ||||
| Total Asset | 615.89 M | ||||
| Retained Earnings | (568.78 M) | ||||
| Working Capital | 561.44 M | ||||
| Current Asset | 11.95 M | ||||
| Current Liabilities | 5.72 M | ||||
About Keros Therapeutics Performance
Assessing Keros Therapeutics' fundamental ratios provides investors with valuable insights into Keros Therapeutics' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Keros Therapeutics is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | (218.58) | (207.65) | |
| Return On Tangible Assets | (0.30) | (0.32) | |
| Return On Capital Employed | (0.36) | (0.38) | |
| Return On Assets | (0.30) | (0.32) | |
| Return On Equity | (0.33) | (0.34) |
Things to note about Keros Therapeutics performance evaluation
Checking the ongoing alerts about Keros Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Keros Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Keros Therapeutics generated a negative expected return over the last 90 days | |
| Keros Therapeutics has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 3.55 M. Net Loss for the year was (187.35 M) with loss before overhead, payroll, taxes, and interest of (14.74 M). | |
| Keros Therapeutics currently holds about 215.62 M in cash with (160.87 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.37. | |
| Over 98.0% of the company shares are owned by institutional investors | |
| Latest headline from kalkinemedia.com: How Has Keros Therapeutics Attracted Institutional Capital |
- Analyzing Keros Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Keros Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Keros Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Keros Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Keros Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Keros Therapeutics' stock. These opinions can provide insight into Keros Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Keros Stock Analysis
When running Keros Therapeutics' price analysis, check to measure Keros Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Keros Therapeutics is operating at the current time. Most of Keros Therapeutics' value examination focuses on studying past and present price action to predict the probability of Keros Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Keros Therapeutics' price. Additionally, you may evaluate how the addition of Keros Therapeutics to your portfolios can decrease your overall portfolio volatility.